Delivery Order SPE2DB22D2206-SPE2DB25FJV84
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,662.53 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units). This firm fixed price, competitively awarded delivery order was issued on March 12, 2025, with an ultimate completion date of March 13, 2025. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.50 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 5, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $14,837.30 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets (30-count units) under a firm fixed-price contract. This award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a non-set-aside competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $7,024.00 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 20, 2025, with performance to be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) with a ceiling value of $9,939.09 under a firm fixed-price contract. This award, made on April 23, 2025, with an ultimate completion date of April 24, 2025, represents a non-set-aside competitive procurement. The contractor will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $15,809.81 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed price contract. The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order represents a purchase of a branded pharmaceutical product for military healthcare support, with performance to be fulfilled at the contractor's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $7,102.01 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. The award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where the vendor maintains its...
- The Defense Logistics Agency awarded a delivery order valued at approximately $23,000 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in unit of issue 30-count packages. This competitively awarded, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The contract represents a non-set-aside procurement, and performance will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV84Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,234.78 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and represents a non-competitive, non-set-aside procurement. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a wide range of pharmaceutical products, medical supplies, and specialty medications to support military healthcare programs worldwide. The DLA Troop Support Medical contract demonstrates the contractor's significant role in supporting the Defense Health Agency and other federal healthcare systems with essential brand-name and generic pharmaceuticals across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 9/9/25 |